Biologic control of injury and inflammation: Much more than too little or too late

被引:80
作者
Guirao, X [1 ]
Lowry, SF [1 ]
机构
[1] CORNELL UNIV MED COLL, NEW YORK HOSP, LAB SURG METAB, DEPT SURG, NEW YORK, NY 10021 USA
关键词
D O I
10.1007/s002689900069
中图分类号
R61 [外科手术学];
学科分类号
摘要
A generalized host inflammatory response is necessary to orchestrate the maintenance or recovery of tissue repair and immune competence following severe injury or infection. When excessive in initial magnitude or duration, however, these otherwise beneficial inflammatory processes may eventuate in deterioration rather than restoration of homeostasis. Although the adverse consequences of excessive inflammatory stimuli may be acutely evident, their influences are more often insidious, A complex cascade of endogenously derived proinflammatory mediators are currently hypothesized to be responsible for both the beneficial and the adverse sequelae of infection and injury. The cytokine proteins tumor necrosis factor and interleukin 1 have been most widely studied as potential targets for antagonist intervention in both experimental models and prospective clinical trials. Preclinical evidence supporting these approaches is briefly discussed herein, as are the results of clinical trials attempting to modulate cytokine influences in the presence of sepsis, The present discussion focuses on potential insights gained from these investigations and the evolving appreciation for the importance of cytokine counterregulatory mechanisms. Examples of potentially complex interactions between inflammatory cytokines and infection-induced antagonist proteins or counterregulatory hormones are provided, It is hypothesized that a sustained imbalance among these proinflammatory and counterregulatory influences may be a critical determinant of outcome in patients with severe infection.
引用
收藏
页码:437 / 446
页数:10
相关论文
共 135 条
[1]   EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL [J].
ABRAHAM, E ;
WUNDERINK, R ;
SILVERMAN, H ;
PERL, TM ;
NASRAWAY, S ;
LEVY, H ;
BONE, R ;
WENZEL, RP ;
BALK, R ;
ALLRED, R ;
PENNINGTON, JE ;
WHERRY, JC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12) :934-941
[2]  
ADERKA D, 1991, CANCER RES, V51, P5602
[3]   BIOLOGY OF MULTIFUNCTIONAL CYTOKINES - IL-6 AND RELATED MOLECULES (IL-1 AND TNF) [J].
AKIRA, S ;
HIRANO, T ;
TAGA, T ;
KISHIMOTO, T .
FASEB JOURNAL, 1990, 4 (11) :2860-2867
[4]   A RECOMBINANT HUMAN RECEPTOR ANTAGONIST TO INTERLEUKIN-1 IMPROVES SURVIVAL AFTER LETHAL ENDOTOXEMIA IN MICE [J].
ALEXANDER, HR ;
DOHERTY, GM ;
BURESH, CM ;
VENZON, DJ ;
NORTON, JA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (04) :1029-1032
[5]   DIFFERENTIAL ALTERATIONS IN PLASMA IL-L AND TNF LEVELS AFTER TRAUMA AND HEMORRHAGE [J].
AYALA, A ;
WANG, P ;
BA, ZF ;
PERRIN, MM ;
ERTEL, W ;
CHAUDRY, IH .
AMERICAN JOURNAL OF PHYSIOLOGY, 1991, 260 (01) :R167-R171
[6]   DIVERGENT EFFICACY OF ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA IN INTRAVASCULAR AND PERITONITIS MODELS OF SEPSIS [J].
BAGBY, GJ ;
PLESSALA, KJ ;
WILSON, LA ;
THOMPSON, JJ ;
NELSON, S .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (01) :83-88
[7]   INFLUENCE OF HYPERCORTISOLEMIA ON SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR-II AND INTERLEUKIN-1 RECEPTOR ANTAGONIST RESPONSES TO ENDOTOXIN IN HUMAN-BEINGS [J].
BARBER, AE ;
COYLE, SM ;
FISCHER, E ;
SMITH, C ;
VANDERPOLL, T ;
SHIRES, T ;
LOWRY, SF .
SURGERY, 1995, 118 (02) :406-411
[8]  
BARBER AE, 1993, J IMMUNOL, V150, P1999
[9]   AN OVERVIEW OF MORTALITY RISK PREDICTION IN SEPSIS [J].
BARRIERE, SL ;
LOWRY, SF .
CRITICAL CARE MEDICINE, 1995, 23 (02) :376-393
[10]   PROTECTIVE ROLE OF INTERLEUKIN-6 IN THE LIPOPOLYSACCHARIDE-GALACTOSAMINE SEPTIC SHOCK MODEL [J].
BARTON, BE ;
JACKSON, JV .
INFECTION AND IMMUNITY, 1993, 61 (04) :1496-1499